JAK1 is a direct target of miR-1225. (a) Graphical representation of the conserved miR-1225 binding motif at the 3′-UTR of JAK1
microRNA-1225 inhibit apoptosis of pancreatic cancer cells via targeting JAK1
This study explored the role of microRNA-1225 (miR-1225) in pancreatic cancer (PC). miR-1225 was upregulated in PC tissues and cell lines, especially in patients with poor prognosis. Inhibition of miR-1225 suppressed proliferation, induced apoptosis, and reduced tumor growth in vivo. Mechanistically, miR-1225 directly targets the 3'UTR of JAK1, downregulating its expression and inactivating JAK/STAT signaling. Silencing JAK1 reversed the effects of miR-1225 inhibition. These findings suggest miR-1225 acts as an oncogene in PC by targeting JAK1, offering potential therapeutic targets.
Key Findings
Key findings: (1) miR-1225 expression is significantly upregulated in pancreatic cancer tissues and cell lines, correlating with poor prognosis. (2) Inhibition of miR-1225 suppresses cell proliferation, colony formation, and xenograft tumor growth, while promoting apoptosis in PANC-1 and AsPC-1 cells. (3) Dual-luciferase reporter assay confirmed that miR-1225 directly binds to the 3'-untranslated region of JAK1, leading to its downregulation. (4) JAK1 and its downstream effector STAT3 are downregulated in PC tissues and cells; miR-1225 inhibition restores JAK1/STAT3 expression. (5) Silencing JAK1 counteracts the pro-apoptotic and anti-proliferative effects of miR-1225 inhibition, confirming that miR-1225 exerts its oncogenic function partly through the JAK/STAT pathway. These results highlight miR-1225 as a potential therapeutic target for pancreatic cancer.
Contribution
Creative Biogene provided the miR-1225 inhibitor and negative control inhibitor essential for this study. These chemically modified double-stranded miRNAs enabled efficient silencing of endogenous miR-1225, allowing investigation of its role in pancreatic cancer cell proliferation, apoptosis, and JAK1 regulation.